Sprint to the Science and Technology Innovation Board! 2 pharmaceutical IPOs will be on the meeting

According to the information of the new stock meeting of Oriental Fortune Network, there will be 11 new stocks on the meeting, including 2 pharmaceutical new stocks, namely Chongqing Zhixiang Jintai Biopharmaceutical Co.
, Ltd.
and Yisheng Biotechnology (Shanghai) Co.
, Ltd
。 Zhixiang Jintai: 91.
68 million shares will be issued this time According to the prospectus of Zhixiang Jintai's initial public offering and listing on the Science and Technology Innovation Board (Declaration Draft), the number of shares issued by the issuer this time is 91.
68 million shares (excluding the number of shares issued by over-allotment option), which does not involve shareholders' public offering of shares, and the number of public shares issued accounts for 25.
00% of the total share capital after this offering, with a par value of RMB 1.
00 per share, and a total share capital of 367 million shares
after issuance 。 Zhixiang Jintai is an innovation-driven biopharmaceutical company, whose main products are monoclonal antibody drugs and bispecific antibody drugs
in the therapeutic areas of autoimmune diseases, infectious diseases and tumors 。 From the perspective of product pipeline progress, as of the signing date of this prospectus, Zhixiang Jintai has 12 products under development, of which GR1501 for moderate to severe plaque psoriasis and radiologically positive axial spondyloarthritis are in phase III clinical trials, GR1801 for passive immunity indications after suspected rabies virus exposure and GR1802 for moderate to severe asthma are in phase II clinical trials, GR1603 and GR1803 are in phase I clinical trials, GR1901 has obtained the Notice of Clinical Trial Approval of Drugs, and 6 more products are in the preclinical research stage
.
As the core products have not yet been put on the market, Zhixiang Jintai has not yet made a profit, and as of December 31, 2021, the cumulative uncovered loss in the company's consolidated financial statements was -194 million yuan
.
In the coming period, the company is expected to continue to lose money, and the accumulated uncovered losses will continue to expand
.
However, the company's R&D investment has increased year by year, and in 2019, 2020 and 2021, the company's R&D expenses were 125 million yuan, 228 million yuan and 295 million yuan
respectively.
The company expects to continue to invest
in R&D on a large scale in the future.
Yisheng Biotechnology: The issuance of no more than 21,033,500 shares According to the prospectus (declaration draft) of Yisheng Biotechnology's initial public offering and listing on the Science and Technology Innovation Board, the issuance of no more than 21,033,500 shares (excluding the number of shares issued by over-allotment option), and the number of shares issued by the public offering shall not be less than 25%
of the total share capital of the company after this offering.
All of the issuance was a new offering, and the original shareholders did not offer shares
to the public.
The par value of each share is 1.
00 yuan, and the total share capital after issuance does not exceed 84,133,710 shares
.
The company is a biotechnology enterprise driven by protein modification and enzyme evolution technology, focusing on the upstream core raw materials of the life science industry chain, engaged in the research and development, production and sales of molecular, protein and cellular biological reagents, and its products can be applied to life science research, diagnosis and testing, and biomedicine and other fields
.
It is understood that since 2020, Yisheng Biotechnology, as an upstream raw material supplier of detection reagents, has achieved related product sales growth
.
In 2020 and 2021, the sales revenue of the company's related products was 46.
1476 million yuan and 81.
7413 million yuan, respectively, accounting for 24.
77% and 25.
42%
of the current operating income.
However, due to the short establishment of the company, the small scale of the enterprise and the relatively single financing channels, the cumulative R&D investment in the past three years is 93.
7587 million yuan, which is still a big gap
in technology accumulation compared with international enterprises such as Thermo Fisher, Danaher, Bó Lè, and Kaijie.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.